SVF
Level D· Preclinical EvidenceAnimal Study

Fat grafting based on 3D printed polyhydroxyalkanoate scaffolds.

Gan L., Ouyang P., Lan Y., Li H., Zhang X., Liu X.

Animal Study on Face & Skin, published in Biomater Adv (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomater Adv (2026)
Country
Netherlands
Reported sample size
—
PMID
41043309
DOI
10.1016/j.bioadv.2025.214512

Abstract (original English)

Autologous fat grafting holds significant promise for soft tissue repair and reconstruction. However, its clinical application faces challenges, including insufficient graft strength for optimal shaping and poor long-term retention rates, particularly in large-volume transplantation. Three-dimensional (3D)-printed biodegradable scaffolds offer a potential solution by mitigating graft ischemia and hypoxia, thereby improving retention, while offering temporary mechanical support before degradation. Polyhydroxyalkanoates (PHA) containing 3-hydroxybutyrate and 4-hydroxybutyrate monomers, a promising class of biomaterials in tissue engineering, were employed in this study to fabricate 3D-printed scaffolds for fat grafting. Their effects on graft retention were explored for underlying mechanisms. In vivo studies demonstrated that 3D-printed PHA scaffolds significantly enhanced fat graft retention by stimulating angiogenesis, promoting adipocyte viability, inducing macrophage polarization toward the M2 phenotype, attenuating oxidative stress, and optimizing mitochondrial functions. Additionally, the scaffolds further improved retention by facilitating beige adipogenesis or white adipose tissue browning. In vitro experiments confirmed the excellent biocompatibility of PHA, with its degradation product -3-hydroxybutyrate (3HB) exhibiting no cytotoxicity. Furthermore, 3HB enhanced the en

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
PolyhydroxyalkanoatesTissue ScaffoldsPrinting, Three-DimensionalAnimalsTissue EngineeringAdipose TissueMiceBiocompatible Materials3-Hydroxybutyric AcidAdipocytes
Face & Skin
View on PubMedDOI

Related research